Clinical Trials Logo

Filter by:
NCT ID: NCT05961462 Completed - Long COVID-19 Clinical Trials

Effects of Exercise Training on Patients With Long COVID-19

Start date: January 10, 2023
Phase: N/A
Study type: Interventional

Effects of Exercise training on Patients With Long COVID-19, is a single-center, randomized, controlled trial designed to evaluate the effects of 4- week aerobic exercise administered to patients with long COVID-19 symptoms. The main outcome is cardiopulmonary fitness and long COVID-19 symptom improvement. Quality of life, depression, anxiety, insomnia status and perceived stress will also be assessed before and after the exercise program.

NCT ID: NCT05961358 Recruiting - Anesthesia Clinical Trials

Auxiliary Anesthesia Technique for Extracting Advanced Hemodynamic Parameters Based on Peripheral Arterial Waveform Photography

Start date: August 1, 2023
Phase:
Study type: Observational

In this study, the arterial blood pressure waveform was digitized by snapshots or videos of the patient monitor to further estimate advanced hemodynamic parameters, so as to realize continuous and automatic monitoring of advanced hemodynamics on mobile devices to assist anesthesia, with a view to developing an Android/iOS application for mobile devices and application in patient management.

NCT ID: NCT05961202 Recruiting - Myocarditis Clinical Trials

The Effects of Hydroxychloroquine in Patients With Inflammatory Cardiomyopathy

HYPIC
Start date: January 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Evaluating the long-term therapeutic effects of hydroxychloroquine(compared to glucocorticoid therapy alone) in patients with inflammatory cardiomyopathy--a multicenter randomized controlled study

NCT ID: NCT05961111 Recruiting - Breast Cancer Clinical Trials

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

Start date: June 24, 2023
Phase: Early Phase 1
Study type: Interventional

20 participants are expected to be enrolled for this open,Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.

NCT ID: NCT05961007 Suspended - Clinical trials for Diabetic Macular Edema

Evaluation of IBI302 Injection in nAMD or DME

Start date: November 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of intravitreal IBI302 in the treatment of subjects with neovascular age-related macular degeneration (only in Phase I) or diabetic macular edema.

NCT ID: NCT05960955 Recruiting - Clinical trials for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Start date: November 13, 2023
Phase: Phase 2
Study type: Interventional

This trial is a Phase II study. All patients are resectable Gastric or Gastroesophageal Junction Adenocarcinoma, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.The purpose of this study is to evaluate the efficacy and safety of cadonilimab combined with chemotherapy with or without AK117 neoadjuvantin treatment of resectable Gastric or Gastroesophageal Junction Adenocarcinoma.

NCT ID: NCT05960942 Completed - Clinical trials for Autism Spectrum Disorder

Application of Esketamine in Anesthesia of Autism Children

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

Autism Spectrum Disorder (ASD) is a group of serious neurodevelopmental disorders. Autistic children appear with significant frequency for medical services, lots of which requiring procedural sedation or anaesthesia. Autistic children have often been described as difficult to sedate or anesthetize due to a variety of ASD symptoms. It is a challenging task to provide safe and effective sedation during the procedure of colonic TET for FMT in autism children. The investigators intend to explore an optimum anesthetic regimen for autism children undergoing endoscopic procedures.

NCT ID: NCT05960890 Recruiting - Heart Failure Clinical Trials

Cohort Study of Chronic Heart Failure

CHF
Start date: June 8, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the influencing factors of chronic heart failure prognosis in heart failure patients. The main question it aims to answer is that what are the influencing factors of clinical outcomes in chronic heart failure. Participants will be collected multiple omics data such as phenotype group, environmental exposure group, intestinal microbiome, genome, metabolome, and noninvasive biomarkers.

NCT ID: NCT05960721 Recruiting - Atrial Fibrillation Clinical Trials

Low-dose NOAC Versus GDMT After LAAO

RECORD-III
Start date: July 6, 2023
Phase: N/A
Study type: Interventional

The increased risk of Atrial fibrillation (AF) regarding thromboembolic stroke is predominantly due to the formation and embolization of clots from within the left atrial appendage (LAA). Percutaneous left atrial appendage occlusion (LAAO) is a nonpharmacological strategy for stroke prevention in patients with AF. Data from randomized trials, including PROTECT-AF, PREVAIL, and Prague-17, have suggested that LAAO has comparable efficacy to warfarin or NOACs. Considering these results, LAAO was recommended by the American College of Cardiology (ACC) and European Society of Cardiology (ESC) guidelines as a non-pharmacological stroke prevention strategy for patients with NVAF who have contraindications or are unsuitable for OAC. The PROTECT-AF and PREVAIL trials stipulated the use of standardized antithrombotic medications which were designed to minimize the risk of stroke, systemic embolism, or device-related thrombosis. This antithrombotic strategy was subsequently endorsed by the guidelines, briefly, patients with LAAO were discharged on warfarin and aspirin for 45 days post-LAAO, if there was no leak or a leak ≤5 mm under transesophageal echocardiography (TEE) at 45-day follow-up, antithrombotic strategies shall switch to dual antiplatelet therapy (DAPT) until 6 months post-LAAO, and then aspirin thereafter. Although LAAO was recommended by medical societies, previous patient-level meta-analyses have implied that compared with oral anticoagulation, LAAO had significantly more ischemic strokes, suggesting the inability of LAAO to prevent an ischemic stroke from sources beyond LAA. Will a combined strategy of LAAO and OAC further reduce the risk of stroke? The investigators hypothesized that a long-term low dose-Rivaroxaban (10mg daily) post-LAAO might be a potent supplement to the residue risk of ischemic stroke.

NCT ID: NCT05960617 Recruiting - Clinical trials for Glycogen Storage Disease Type IB

Efficacy and Safety of Empagliflozin in GSD-Ib Patients

Start date: July 15, 2023
Phase: Phase 2
Study type: Interventional

Empagliflozin Treatment of GSD-1b patients